Ann: New Independent Trial Data Supports Potential of Veyonda, page-29

vrs you're basing your argument on trying to pick little holes at differences in the patient cohort without acknowledging the whole picture.

I can do the same by pointing to the slide attached which could argue the other way, ie the Lupin cohort had a greater % of 20 lesions or more and were more heavily pre-treated than the warmth group - on these data points you could argue that the Lupin cohort was more advanced and your argument doesn't hold as firmly.

In addition the Lupin results showed a greater % of patients to achieve a PSA reduction (86% vs 73%) and greater % to achieve more than 50% PSA reduction

The comparison is never going to be like for like and was intended to provide a degree of context.

Importantly imo you have not been able to conclude that Veyonda does not provide additional efficacy vs lutetium alone and that's the key part of this.

The Lupin studies are not yet finished either so I look forward to the market's (and your) reaction when 71% is adjusted to +100%!